Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Prime Medicine, Inc. Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates November 12, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Participate in Upcoming Investor Conferences November 06, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress October 24, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings October 15, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Unveils Strategically Focused Pipeline September 30, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies September 30, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers BMY PRME Prime Medicine to Participate in Upcoming Investor Conferences August 28, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates August 08, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present at Upcoming Investor Conferences May 30, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 13, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates May 10, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD) May 08, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference May 01, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) April 29, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings April 23, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates March 01, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Participate in Upcoming Investor Conferences February 28, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares February 20, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Announces Pricing of Upsized Public Offering February 14, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Announces Proposed Public Offering of Common Stock February 14, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 01, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis January 25, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer January 05, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present at Upcoming Investor Conferences November 08, 2023 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates November 03, 2023 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b October 27, 2023 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases October 24, 2023 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences October 17, 2023 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Prime Medicine to Present at Upcoming Investor Conferences September 19, 2023 From Prime Medicine, Inc. Via GlobeNewswire Tickers PRME Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
